Filing Flows › Health Care › Xeris Biopharma Holdings (XERS)
Xeris Biopharma Holdings (XERS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Xeris Biopharma Holdings (XERS) Q3 2026 earnings results →
Q3 2026 Revenue up 44% year over year to $107M · 11¢ of every $1 of revenue kept as net profit · operating margin 15.8%
Xeris Biopharma Holdings made $107M in Q3 2026 (+44% Y/Y): Product revenue, net $106M, Royalty, contract and other revenue $958K. Operating margin 15.8%, net earnings $11.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $107.2M in Q3 2026, up 44% year over year and up 16% from the previous quarter. Recorlev was the largest line at 67% of revenue. Recorlev added $34.6M year over year (up 93%), 105% of the total change. Gvoke declined 14%.
Operating profit was $16.9M, a 15.8% margin (up 6.7 points year over year). Of the extra revenue versus Q3 2025, 31% reached operating profit, above the 9% margin then. Total costs grew 33% against revenue growth of 44%. The fastest-growing cost line was Research & development (+48%). Net earnings were $11.3M, up 1718% year over year. The effective tax rate was 0.0%.
Operating cash flow was $35.5M (up 92% year over year), 314% of net earnings. Non-cash charges added back $300K of depreciation and amortization and $10.8M of share-based compensation. Working capital and other items added $13.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $107M | +44% | 15.8% | $11.3M | $35.5M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $92.1M | +29% | 5.6% | −$31.1M | $8.3M |
| Q1 2026 | 10-Q | May 7, 2026 | $83.1M | +38% | 9.5% | $2.2M | $9.9M |
| Q4 2025 | 10-K | Mar 2, 2026 | $85.8M | +43% | 19.5% | $11.1M | $20.0M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $74.4M | +37% | 9.0% | $621K | $18.4M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $71.5M | +49% | 6.3% | −$1.9M | $182K |
| Q1 2025 | 10-Q | May 8, 2025 | $60.1M | +48% | -5.1% | −$9.2M | −$10.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Xeris Biopharma Holdings
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit. We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
In its own words, from its 10-K, filed Mar 2, 2026.
Xeris Biopharma Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +44% against the peers' median +10%. Operating margin: 15.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Q3 2026 | $107M | +44% | 15.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Xeris Biopharma Holdings 10-Q on SEC EDGAR · CIK 1867096 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns XERS and who is buying
More on XERS
- How Xeris Biopharma Holdings makes money: revenue by segment
- Xeris Biopharma Holdings next earnings date and what analysts expect
- Xeris Biopharma Holdings stock forecast, price target and fair value
- Who owns Xeris Biopharma Holdings stock: holders, funds and Congress trades
- Xeris Biopharma Holdings guidance and outlook
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Xeris Biopharma Holdings guidance history: guided vs reported
- Xeris Biopharma Holdings operating margin by quarter
- Xeris Biopharma Holdings net income by quarter
- Xeris Biopharma Holdings R&D spending by quarter
- Xeris Biopharma Holdings Product revenue, net revenue by quarter
- Xeris Biopharma Holdings Royalty, contract and other revenue revenue by quarter